COPD immune mystery: scientists probe why lungs can't clear bacteria.
NCT ID NCT05743582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why immune cells in people with COPD don't work properly to clear bacteria from the lungs. Researchers will collect cells from the lungs and blood of 189 participants, including COPD patients and healthy smokers and non-smokers. They will study how these cells use energy and respond to bacteria, aiming to find new ways to treat COPD in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new treatments for COPD by targeting immune cell metabolism.
- What could go wrong
- This is an observational study, not a treatment trial. It is early-stage research, and findings may not lead to therapies for years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 189 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
189 participants split evenly into: COPD patients, healthy smokers, healthy non-smokers (63 each)
- Ages
-
18 to 77 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: COPD patients: * COPD patients aged 18-77 years who are GOLD Stage 1 or 2 or 3; for patients undergoing bronchoscopy already for a clinical reason. * COPD patients aged 18-77 years old who are GOLD Stage 1,2 or 3 for patients who are donating blood only. * COPD patients aged 18-69 years who are GOLD Stage 1 or 2 for patients undergoing bronchoscopy for research purposes. * COPD- Defined by radiological investigation of chest either chest X-ray or High-resolution CT scan in previous 12 months * Ability to provide informed consent Healthy volunteers: * Any healthy volunteer aged 18-77 years * Ability to provide informed consent Exclusion Criteria: COPD patients: * Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure. * Individuals with a history of anaemia * Individuals who have donated \>250 ml of blood for any reason within the last 6 months * Individuals who are pregnant or breast feeding. * Current participation in any other clinical trial, except those directly relating to this cohort and study. * Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks * Individuals who have received a vaccine in the past 2 weeks * Inability to communicate in English or convey willingness to participate. * For bronchoscopy - Any significant lung condition that would contra-indicate bronchoscopy including: active acute lung infection (with the exception of asymptomatic pulmonary colonisation) or malignancy, significant coexisting interstitial lung disease or additional pulmonary diagnosis in addition to COPD. Healthy volunteers: * Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure * Individuals with anaemia on the screening full blood count (FBC) * Individuals who donated \>250 ml of blood for any reason within the last 6 months * Individuals who are pregnant or breast feeding * Current participation in any other clinical trial * Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks. * Individuals who have received a vaccine in the past 2 weeks * Chronic or acute respiratory disease. * Any chronic medical condition or receipt of regular prescription medication other than the oral contraceptive pill. * Inability to communicate in English or convey willingness to participate * For bronchoscopy - Any active lung condition including any lung infection or asthma Any significant abnormality on CXR that would contraindicate bronchoscopy FEV1 \<65% predicted (BTS Guidelines, 2001)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Royal Infirmary of Edinburgh
RECRUITINGEdinburgh, EH16 5SA, United Kingdom
-
University of Edinburgh
NOT_YET_RECRUITINGEdinburgh, EH16 4TJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a COPD flare stun the heart? study watches for hidden strain
- Can better training get doctors to talk about what matters most to dying veterans?
- Can an injected antibody calm inflamed lungs and cut COPD flare-ups?
- Detailed lung scans could map COPD damage more precisely
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Fine-Mist inhalers aim to reach deep lungs in COPD